| Timothy W Bax, MD | |
|
217 W Cataldo Ave Fl 3, Spokane, WA 99201-2217 | |
| (509) 747-6194 | |
| (509) 838-0824 |
| Full Name | Timothy W Bax |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 32 Years |
| Location | 217 W Cataldo Ave Fl 3, Spokane, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255303301 | NPI | - | NPPES |
| 0305781 | Other | WA | LABOR & INDUSTRIES |
| P0121507 | Other | WA | RAILROAD MEDICARE |
| 1005968 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD00036060 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prov Sacred Hrt Med Ctr & Childs Hosp. | Spokane, WA | Hospital |
| Providence Holy Family Hospital | Spokane, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Washington | 0345139929 | 687 |
News Archive
Scientists at Barrow Neurological Institute have recently made discoveries about use of a new technology for imaging brain tumors in the operating room - a finding that could have important implications for identifying and locating invading cells at the edge of a brain tumor.
Oxford Gene Technology (OGT), The Molecular Genetics Company, is today launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay.
A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.
Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.
› Verified 4 days ago
| Entity Name | Columbia Surgical Specialists, Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417067372 PECOS PAC ID: 2860305505 Enrollment ID: O20031110000300 |
News Archive
Scientists at Barrow Neurological Institute have recently made discoveries about use of a new technology for imaging brain tumors in the operating room - a finding that could have important implications for identifying and locating invading cells at the edge of a brain tumor.
Oxford Gene Technology (OGT), The Molecular Genetics Company, is today launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay.
A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.
Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.
› Verified 4 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194099390 PECOS PAC ID: 0345139929 Enrollment ID: O20040311001453 |
News Archive
Scientists at Barrow Neurological Institute have recently made discoveries about use of a new technology for imaging brain tumors in the operating room - a finding that could have important implications for identifying and locating invading cells at the edge of a brain tumor.
Oxford Gene Technology (OGT), The Molecular Genetics Company, is today launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay.
A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.
Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy W Bax, MD Po Box 421, Liberty Lake, WA 99019-0421 Ph: (866) 747-2455 | Timothy W Bax, MD 217 W Cataldo Ave Fl 3, Spokane, WA 99201-2217 Ph: (509) 747-6194 |
News Archive
Scientists at Barrow Neurological Institute have recently made discoveries about use of a new technology for imaging brain tumors in the operating room - a finding that could have important implications for identifying and locating invading cells at the edge of a brain tumor.
Oxford Gene Technology (OGT), The Molecular Genetics Company, is today launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay.
A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.
Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.
› Verified 4 days ago
Paul C Thorne, MD Surgery Medicare: Medicare Enrolled Practice Location: 101 W 8th Ave, Ste 100, Spokane, WA 99204 Phone: 509-474-5445 Fax: 509-462-4086 | |
Mary Cristina Smith, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 62 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-456-0262 Fax: 509-462-5059 | |
Dr. Dara Heisler Christante, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 217 W Cataldo Ave Fl 3, Spokane, WA 99201 Phone: 509-624-2326 Fax: 509-252-2509 | |
Janet S Abadir, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 105 W 8th Ave, Ste 7010, Spokane, WA 99204 Phone: 509-747-6194 Fax: 509-838-0824 | |
Dr. Luke Xiaoli Zhan, M.D., PH.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 122 W 7th Ave, Suite 420, Spokane, WA 99204 Phone: 509-626-9440 Fax: 509-626-9475 | |
Paul E Myers, MD Surgery Medicare: Medicare Enrolled Practice Location: 910 W 5th Ave, Suite 800, Spokane, WA 99204 Phone: 509-838-2531 | |
Dr. Jenna Kochevar, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 910 W 5th Ave Ste 800, Spokane, WA 99204 Phone: 509-755-5120 Fax: 509-755-6580 |